S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
'Civil War’ continues box-office campaign at No. 1
TSE:APS

Aptose Biosciences (APS) Stock Price, News & Analysis

C$1.69
-0.06 (-3.43%)
(As of 04/19/2024 ET)
Today's Range
C$1.69
C$1.73
50-Day Range
C$1.69
C$2.78
52-Week Range
C$1.69
C$11.40
Volume
20,800 shs
Average Volume
9,029 shs
Market Capitalization
C$26.55 million
P/E Ratio
N/A
Dividend Yield
0.39%
Price Target
N/A
APS stock logo

About Aptose Biosciences Stock (TSE:APS)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

APS Stock Price History

APS Stock News Headlines

Aptose Biosciences's Earnings: A Preview
The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
Closing Bell: Aptose Biosciences Inc flat on Wednesday (APS)
The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
Aptose Reports Results for the Third Quarter 2023
Closing Bell: Aptose Biosciences Inc up on Friday (APS)
Closing Bell: Aptose Biosciences Inc up on Thursday (APS)
Closing Bell: Aptose Biosciences Inc flat on Monday (APS)
Aptose Reports Results for the Second Quarter 2023
Aptose to sell up to $25M stock in the U.S.
See More Headlines
Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
4/21/2024
Next Earnings (Estimated)
5/13/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Net Income
C$-51,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$1.06 per share
Book Value
C$1.03 per share

Miscellaneous

Free Float
N/A
Market Cap
C$26.55 million
Optionable
Not Optionable
Beta
1.44
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. William G. Rice Ph.D. (Age 59)
    Chairman, Pres & CEO
  • Mr. Gregory K. Chow CPA (Age 45)
    MBA, BA, Sr. VP, CFO & Principal Accounting Officer
  • Mr. Ernest Kitt B.S.
    M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell (Age 73)
    Chief Medical Officer
  • Mr. Peter Murray
    Director of Clinical Devel.

APS Stock Analysis - Frequently Asked Questions

How have APS shares performed in 2024?

Aptose Biosciences' stock was trading at C$3.35 at the start of the year. Since then, APS stock has decreased by 49.6% and is now trading at C$1.69.
View the best growth stocks for 2024 here
.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our APS earnings forecast
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (TSE:APS) released its quarterly earnings results on Tuesday, March, 26th. The biotechnology company reported ($1.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.98) by $0.02.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD).

How do I buy shares of Aptose Biosciences?

Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:APS) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners